{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:05:07Z","timestamp":1788109507765,"version":"build-2803163510"},"reference-count":29,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pharmacokinetics, pharmacodynamics and general safety and tolerability of JNJ-42847922, a selective orexin-2 receptor antagonist, were assessed in healthy subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Five consecutive cohorts of healthy subjects were enrolled and received doses of 5\u201360 mg orally once daily over 10 days of JNJ-42847922 ( n=6) or placebo ( n=2). Concentrations of drug in plasma and urine were measured over 24 h after dosing on Days 1, 5 and 10. Observed- and self-reported somnolence was used to evaluate the principal pharmacodynamic effect of JNJ-42847922. A test battery to assess vigilance state, sedation and alertness was assessed at 4, 6 and 8 h after dosing. Safety assessments included recording of adverse events, vital signs, electrocardiograms, clinical laboratory assessments and suicidality per Columbia Suicide Severity Rating Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      JNJ-42847922 was rapidly absorbed after the morning dose administration. The median t\n                      <jats:sub>max<\/jats:sub>\n                      ranged from 0.5\u20131.5 h and mean t\n                      <jats:sub>1\/2<\/jats:sub>\n                      values from 2\u20133 h. At JNJ-42847922 dose levels \u2a7e20 mg, mean C\n                      <jats:sub>max<\/jats:sub>\n                      and mean area under the curve, values increased less than dose proportionally. At doses \u2a7e20 mg, JNJ-42847922 consistently induced somnolence on all study days. At four hours post-dose administration, dose levels &gt;5 mg JNJ-42847922 were identified as sedating by the Addiction Research Center Inventory-49. Except for a mild decrease in attention (Bond and Lader Visual Analogue Scale Factor 1) at dose levels &gt;10 mg at four hours post-dose, no clinically relevant changes in other central measures have been observed. JNJ-42847922 was well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0269881118791521","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T07:05:27Z","timestamp":1536131127000},"page":"1330-1340","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-455X","authenticated-orcid":false,"given":"Peter D","family":"van der Ark","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine Neuroscience, Janssen Research and Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Golor","sequence":"additional","affiliation":[{"name":"PAREXEL GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"van Nueten","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine Neuroscience, Janssen Research and Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Nandy","sequence":"additional","affiliation":[{"name":"Department of Global Clinical Pharmacology, Janssen Research and Development US, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-7462","authenticated-orcid":false,"given":"Peter","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine Neuroscience, Janssen Research and Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"bibr1-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111408954"},{"key":"bibr2-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.225466"},{"key":"bibr3-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1974.tb02285.x"},{"key":"bibr4-0269881118791521","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1096\/fasebj.30.1_supplement.1235.4","volume":"30","author":"Briggs L","year":"2016","journal-title":"FASEB J"},{"key":"bibr5-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1038\/nm1544"},{"key":"bibr6-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.1.322"},{"key":"bibr7-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.152009"},{"key":"bibr8-0269881118791521","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2014.00028"},{"key":"bibr9-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1007\/BF02584088"},{"key":"bibr10-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.19.10911"},{"key":"bibr11-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3903-15.2016"},{"key":"bibr12-0269881118791521","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6116"},{"key":"bibr13-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0172-7"},{"key":"bibr14-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.297"},{"key":"bibr15-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112448946"},{"key":"bibr16-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2015.09.002"},{"key":"bibr17-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705610"},{"key":"bibr18-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1887-05.2005"},{"key":"bibr19-0269881118791521","first-page":"2851","volume":"231","author":"Leufkens TR","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"bibr20-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12415"},{"key":"bibr21-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.06.032"},{"key":"bibr22-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998"},{"key":"bibr23-0269881118791521","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0106"},{"key":"bibr24-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80949-6"},{"key":"bibr25-0269881118791521","first-page":"259","volume":"36","author":"Sun H","year":"2013","journal-title":"Sleep"},{"key":"bibr26-0269881118791521","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.02.058"},{"key":"bibr27-0269881118791521","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.7487"},{"key":"bibr28-0269881118791521","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00109"},{"key":"bibr29-0269881118791521","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.6030"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881118791521","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881118791521","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881118791521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:07:49Z","timestamp":1777507669000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881118791521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1177\/0269881118791521"],"URL":"https:\/\/doi.org\/10.1177\/0269881118791521","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]}}}